ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Human Leukocyte Antigen Mismatches Between Donor-Recipient or Donor-Donor are Not Associated with Adverse Pancreas Outcomes in Pancreas After Kidney Transplant Recipients

S. Parajuli, D. Kaufman, B. Welch, H. Sollinger, D. Mandelbrot, J. Odorico

University of Wisconsin, MADISON, WI

Meeting: 2021 American Transplant Congress

Abstract number: 1229

Keywords: Major histocompatibility complex (MHC), Pancreas transplantation

Topic: Clinical Science » Pancreas » Pancreas and Islet: All Topics

Session Information

Session Name: Pancreas and Islet: All Topics

Session Type: Poster Abstract

Session Date & Time: None. Available on demand.

Location: Virtual

*Purpose: A greater degree of HLA mismatch has been previously associated with inferior graft survival in kidney and pancreas transplantation. Pancreas after kidney (PAK) recipients are in a unique situation. On one hand, these recipients have been immunosuppressed for months to years before their pancreas transplant, and on the other hand, they will be exposed to new HLAs from the pancreas donor. How pancreas outcomes among HLA mismatched PAK recipients might differ depending on whether there is a mismatch between pancreas donor and recipient (PD-R) or pancreas donor and kidney donor (PD-KD) are unknown.

*Methods: All primary PAK transplants between 1997 and 2019 at our center were included in this study. Patients were divided into two groups based on the degree of HLA mismatching: low (L-MM) as 0-4 and high (H-MM) as 5-6. We analyzed all (N=73) PAK for PD-R mismatch during the study period, and the subset of PAKs in whom both kidney and pancreas were transplanted at our center for PD-KD mismatch (N=37). Pancreas graft survival and rejection rates were determined over the entire time period.

*Results: The mean interval between kidney and pancreas transplants in the PD-R cohort was 45.2 months. Comparing L-MM (n=39) and H-MM (n=34), we observed no difference in the overall rate of graft loss. 64% of grafts failed (46% death censored, DCGF) in the L-MM group and 62% (26% DCGF) in H-MM (p=0.84). There was also no difference in the overall rate of rejection throughout the whole period [L-MM (33%) vs H-MM (41%)], nor the severity of rejection. We observed a statistically significantly (p<0.01) earlier time to acute pancreas rejection in the H-MM group (6.8 +/- 8.7 mo) vs the L-MM cohort (29.0 +/- 36.2 mo). When stratified according to the type of pancreas transplant induction agent, we observed the overall acute rejection rates to be similar: L-MM(depletional) 33%(6/18), L-MM (IL-2RA) 33% (7/21), H-MM (depletional) 41% (7/17), and H-MM (IL-2RA) 41% (7/17). For the analyses PD-KD subset, 37 recipients had both organs transplanted at our center: 15 were in L-MM and 22 in H-MM. The mean interval between two transplants were 31.2 months. We observed no statistically significant difference in the incidence of pancreas graft loss: 53% grafts failed (27% DCGF) in L-MM and 68 % (41% DCGF) in the H-MM group ( p=0.37). We observed no statistically significant difference in the incidence or severity of rejection. When stratified according to the type of pancreas transplant induction agent, the overall acute rejection rates were similar.

*Conclusions: We did not find a negative impact of HLA mismatch among PAK recipients on either pancreas graft survival or rejection rates.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Parajuli S, Kaufman D, Welch B, Sollinger H, Mandelbrot D, Odorico J. Human Leukocyte Antigen Mismatches Between Donor-Recipient or Donor-Donor are Not Associated with Adverse Pancreas Outcomes in Pancreas After Kidney Transplant Recipients [abstract]. Am J Transplant. 2021; 21 (suppl 3). https://atcmeetingabstracts.com/abstract/human-leukocyte-antigen-mismatches-between-donor-recipient-or-donor-donor-are-not-associated-with-adverse-pancreas-outcomes-in-pancreas-after-kidney-transplant-recipients/. Accessed May 9, 2025.

« Back to 2021 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences